With 20.45 million shares changed hands, the volume of the stock remained lighter than its average volume of 20.6 million shares. The 52-week range on RXRX shows that it touched its highest point at $12.36 and its lowest point at $3.79 during that stretch. It currently has a 1-year price target of $7.00. Beta for the stock currently stands at 0.86.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RXRX was up-trending over the past week, with a rise of 0.84%, but this was down by -25.22% over a month. Three-month performance dropped to -44.34% while six-month performance fell -30.33%. The stock lost -53.50% in the past year, while it has lost -38.17% so far this year. A look at the trailing 12-month EPS for RXRX yields -1.78 with Next year EPS estimates of -1.22. For the next quarter, that number is -0.36. This implies an EPS growth rate of 15.09% for this year and 14.90% for next year. EPS is expected to grow by 19.85% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -35.28%.
Float and Shares Shorts:
At present, 399.15 million RXRX shares are outstanding with a float of 310.78 million shares on hand for trading.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RXRX since 3 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.45054 being high and -$1.62696 being low. For RXRX, this leads to a yearly average estimate of -$1.53875. Based on analyst estimates, the high estimate for the next quarter is -$0.27 and the low estimate is -$0.35. The average estimate for the next quarter is thus -$0.32.
